Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck & Co.'s new drug application for cholesterol-lowering compound Cordaptive has been accepted for standard review by the FDA, according to the company.
Subscribe to our email newsletter
Merck said that it anticipates FDA action in the second quarter of 2008. The company added that it is also moving forward as planned with filings in countries outside the US.
Cordaptive is an investigational compound containing Merck's own extended-release niacin and laropiprant, a novel flushing pathway inhibitor designed to reduce flushing often associated with niacin treatment.
Data included in the application support the proposed use of Cordaptive, either alone or with a statin, as adjunctive therapy to diet for the treatment of elevated LDL cholesterol (LDL-C or “bad” cholesterol), low HDL cholesterol (HDL-C or “good” cholesterol) and elevated triglycerides levels. All are conditions associated with increased risk of heart disease.
Niacin is widely recognized as an effective lipid-modifying therapy; however, treatment has been limited as a result of the flushing side effect.